Monoamine transports have shown promising treatment for different types of psychotropic diseases. As one of the top CRO companies in the field of antagonist discovery for psychiatric disorders therapy, Creative Biolabs has focused on monoamine transporters antagonist development services for years and has accomplished numerous challenging projects in this field. Equipped with deep knowledge and experience in drug design, we can offer high-quality custom monoamine transporters antagonist solutions for our valued clients.
Introduction to Monoamine Transporters
Monoamine transporters play a significant role in regulating the process of neurotransmitter via the absorption of dopamine transporter (DAT), serotonin transporter (SERT), as well as norepinephrine transporter (NET). Currently, monoamine transporters have been regarded as suitable targets for a wide collection of drugs, such as antidepressants, psychotropic drugs, and drugs for the treatment of neurodegenerative disorders. Therefore, many efforts have been made to reveal the function, regulation, and mechanism of action (MOA) of monoamine transporters in different disease models. Until now, great progress has been made in the study of structural characterization of serotonin transporters. Moreover, these results provide data support for the understanding of their transport function and interactions. Besides, a variety of monoamine transporters antagonists have been generated by using different monoamine transporters, including DAT, SERT, or NET. The data have suggested that these antagonists have a similar affinity for other transporters.
Our Monoamine Transporters Antagonist Discovery Platform
Nowadays, monoamine transporters antagonists have a promising role in the prevention or treatment of psychiatric disorders. To develop a new class of psychotropic drugs, Creative Biolabs has established a well-mature monoamine transporter antagonist discovery platform to offers a complete monoamine transporters service chain, ranging from target identification, drug design, drug discovery to commercialization. Our platform equipped with state-of-the-art facilities and highly experienced staff are available to assist in all areas of monoamine transporters antagonist discovery projects, including but not limited to:
Fig.1 Mechanism of monoamine neurotransmission in antidepressant-induced weight gain. (Lee, 2016)
Selective serotonin reuptake inhibitors (SSRIs) are a family of antidepressants that are widely used for treating depressive illness. The results have proven that SSRIs are one of the safest and most effective drugs without causing severe side effects in clinical use. Moreover, recent studies have demonstrated that SSRIs can increase the levels of serotonin in the brain and inhibit the reuptake of serotonin into neurons to trigger antidepression responses in disease therapy. Creative Biolabs has developed a novel SSRI development platform to design new SSRIs for improving the efficacy of conventional SSRIs in various psychiatric disorders.
In Creative Biolabs, our integrated team offers a series of 5-HT receptors-mediated solutions for developing novel antagonists in psychiatric disorders treatment. In general, our methods for 5-HT receptors antagonist discovery are based on a full range of assays, such as in vitro viability and apoptosis assays, ADME and physicochemical assays, and in vivo efficacy models.
In the past few years, many scientists have dedicated themselves to generating novel NET antagonists for the treatment of psychiatric disorders. As a leader in the field of psychiatric drug discovery, our expert team has designed a large number of small molecule NET receptor antagonists to treat psychiatric disorders.
Creative Biolabs can provide a panel of selective norepinephrine reuptake inhibitor (SNRI) development services to prevent the reuptake of both serotonin and norepinephrine. Furthermore, we also provide SNRI characteristics and pharmacological properties analysis services to help improve their performances in the clinic.
Recently, Creative Biolabs offers a wide array of dopamine transporter antagonist discovery services to design safer and more effective antagonists. Recent reports conducted by our labs have suggested that our antagonists can inhibit the release of phorbol ester-induced dopamine and prevent the dopamine transporter phosphorylation, which improves its potency in psychiatric disorders treatments.
Through our full spectrum of early discovery, nonclinical, and commercialization services, Creative Biolabs is committed to developing the most promising monoamine transporters antagonist for our clients. In particular, we have established an advanced monoamine transporters-based antagonist discovery platform which enables us to offer a series of high-quality products for treating many psychiatric disorders. If you are interested in our services, please contact us or send us an inquiry.
Reference
-
Lee, S. H.; et al. Is increased antidepressant exposure a contributory factor to the obesity pandemic? Translational psychiatry. 2016, 6(3): e759-e759. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.
